A retrospective clinical audit of general practices in Australia to determine the motivation for switch to dolutegravir/abacavir/lamivudine and clinical outcomes.

about

A retrospective clinical audit of general practices in Australia to determine the motivation for switch to dolutegravir/abacavir/lamivudine and clinical outcomes.

Item

http://www.wikidata.org/entity/Q47321307

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

A retrospective clinical audit ...... ivudine and clinical outcomes.

@en

A retrospective clinical audit ...... ivudine and clinical outcomes.

@nl

type

Item

label

A retrospective clinical audit ...... ivudine and clinical outcomes.

@en

A retrospective clinical audit ...... ivudine and clinical outcomes.

@nl

prefLabel

A retrospective clinical audit ...... ivudine and clinical outcomes.

@en

A retrospective clinical audit ...... ivudine and clinical outcomes.

@nl

P1476

A retrospective clinical audit ...... ivudine and clinical outcomes.

@en

P2093

Dannae Brown

http://www.w3.org/2001/XMLSchema#string

David Baker

http://www.w3.org/2001/XMLSchema#string

David Orth

http://www.w3.org/2001/XMLSchema#string

Fraser Drummond

http://www.w3.org/2001/XMLSchema#string

Ken Koh

http://www.w3.org/2001/XMLSchema#string

Mark Bloch

http://www.w3.org/2001/XMLSchema#string

Norman Roth

http://www.w3.org/2001/XMLSchema#string

Pedro E Ferrer

http://www.w3.org/2001/XMLSchema#string

Rimgaile Urbaityte

http://www.w3.org/2001/XMLSchema#string

Robert Finlayson

http://www.w3.org/2001/XMLSchema#string

P2860

Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial.

Dolutegravir efficacy at 48 weeks in key subgroups of treatment-naive HIV-infected individuals in three randomized trials.

Brief Report: Dolutegravir Plus Abacavir/Lamivudine for the Treatment of HIV-1 Infection in Antiretroviral Therapy-Naive Patients: Week 96 and Week 144 Results From the SINGLE Randomized Clinical Trial.

Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults: 2016 Recommendations of the International Antiviral Society-USA Panel

Psychiatric Symptoms in Patients Receiving Dolutegravir.

Dolutegravir/abacavir/lamivudine versus current ART in virally suppressed patients (STRIIVING): a 48-week, randomized, non-inferiority, open-label, Phase IIIb study.

Tolerability of integrase inhibitors in a real-life setting.

Intolerance of dolutegravir-containing combination antiretroviral therapy regimens in real-life clinical practice.

Fixed-dose combination dolutegravir, abacavir, and lamivudine versus ritonavir-boosted atazanavir plus tenofovir disoproxil fumarate and emtricitabine in previously untreated women with HIV-1 infection (ARIA): week 48 results from a randomised, open

Switching from efavirenz, emtricitabine, and tenofovir disoproxil fumarate to tenofovir alafenamide coformulated with rilpivirine and emtricitabine in virally suppressed adults with HIV-1 infection: a randomised, double-blind, multicentre, phase 3b,

P304

300-305

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1177/0956462417730474

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28901212

http://www.w3.org/2001/XMLSchema#string

P921

Australia

P932

5794104

http://www.w3.org/2001/XMLSchema#string